---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056198"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:07:49.109436+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nkarta reports Q3 net loss of $22.4M; NKX101 data pushed to 1H 2022

## Summary
- Net loss of $22.4M ($0.68 per share); R&D expense $16.6M, G&A $5.8M.
- Cash, equivalents, restricted cash and short-term investments totaled $259.8M; runway into at least 2H 2023.
- NKX101 Phase 1 data for AML/MDS expected in 1H 2022 (updated from prior guidance).
- First patients dosed in NKX019 Phase 1 for B cell malignancies; initial data expected in 2022.
- Leased new 88,000 sq ft manufacturing facility and HQ to support pivotal trials and commercial launch.

## SEC filing metadata
- accession: 0001564590-21-056198
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000156459021056198/0001564590-21-056198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000156459021056198/nktx-8k_20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056198
- JSON: https://secwatch.observer/filing/0001564590-21-056198.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056198.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.